2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2821 A post-2017 inflection in global acute myeloid leukemia mortality: A sex-specific interrupted time-series analysis, 1990–2023

Gowrishankar Palaniswamy, MD, Harshal Chorya, MBBS2, Nanditha Karra, MD3, Nikhilendhar Nag Mopuru, MD4, Sai Lahari Sangaraju, MD5, Sweta Sahu6
1 Medical University of south carolina (MUSC), Lancaster, United States
2 Medical College Baroda, Vadodara, United States
3 University of Maryland Capital Region Health, Maryland, United States
4 Northwell Health, Vassar Brother Medical Center, Poughkeepsie, New York, United States
5 Berkshire Medical Center, Pittsfield, United States
6 JJM Medical College, Davangere, United States

Background: The therapeutic landscape of acute myeloid leukemia (AML) changed substantially beginning in 2017 with the introduction of molecularly targeted and lower-intensity combination therapies. Whether these advances coincided with measurable changes in population-level AML burden remains uncertain. We evaluated sex-specific changes in global age-standardized AML incidence, mortality, and disability-adjusted life-year (DALY) rates before and after 2017.

Methods: Annual global age-standardized AML incidence, mortality, and DALY rates for males and females from 1990–2023 were obtained from the Global Burden of Disease Study 2023. We prespecified 2017 as the beginning of the modern treatment era. Log-linear regression was used to estimate annual percentage changes for 1990–2016 and 2017–2023. Continuous interrupted time-series models containing time and post-2017 slope terms were used to test whether temporal trajectories changed significantly after 2017. Heteroskedasticity- and autocorrelation-consistent standard errors were applied.

Results: Male age-standardized AML mortality was largely unchanged before 2017 (annual change, 0.03%; 95% CI, −0.10 to 0.16) but declined by 0.81% annually during 2017–2023 (95% CI, −0.90 to −0.72). Interrupted time-series analysis demonstrated a significant post-2017 acceleration in the male mortality decline (slope change, −1.50% per year; P<0.001). Female mortality was already declining before 2017 (−0.56% annually; 95% CI, −0.67 to −0.44) and declined by 0.91% annually during 2017–2023 (95% CI, −1.05 to −0.77), with a significant additional post-2017 slope reduction (−0.68% per year; P=0.001). Male incidence changed from an annual increase of 0.47% before 2017 to a decline of 0.34% during 2017–2023; female incidence changed from −0.04% to −0.42% annually. Post-2017 incidence slope reductions were significant in both males and females (P<0.01). DALY rates declined throughout the study period; no significant post-2017 slope change was identified among males, whereas the rate of decline attenuated among females.

Conclusions: Global AML mortality trajectories improved significantly after 2017, with the most pronounced inflection among males, whose mortality had previously remained nearly stable. Incidence trajectories also shifted downward in both sexes. Although ecological analyses cannot attribute these changes directly to individual therapies, the temporal alignment with rapid expansion of modern AML treatment options suggests emerging population-level progress. Persistent discordance between mortality and DALY trends warrants age-specific and region-specific evaluation of whether therapeutic gains are reaching older and resource-limited populations.

Gowrishankar Palaniswamy, MD: No relevant conflicts of interest to declare.